• Shuffle
    Toggle On
    Toggle Off
  • Alphabetize
    Toggle On
    Toggle Off
  • Front First
    Toggle On
    Toggle Off
  • Both Sides
    Toggle On
    Toggle Off
  • Read
    Toggle On
    Toggle Off
Reading...
Front

Card Range To Study

through

image

Play button

image

Play button

image

Progress

1/14

Click to flip

Use LEFT and RIGHT arrow keys to navigate between flashcards;

Use UP and DOWN arrow keys to flip the card;

H to show hint;

A reads text to speech;

14 Cards in this Set

  • Front
  • Back
most common case of thrombohilia and its tx
vactor v leiden mutation
tx - walfarin 2-6 months( A-Recessive)



walfarin is anticoagulant agent that function by inhibiting the synthesis of vit K dep factors II VII IX X protein S and protein C and may give false positive results for pr S defec
hypercoagulable states
most common is pregnanacy
obesity immobility
malignancy0 adeno carcome- MCC
when it will be increased defect in thrombosis regulation
protein S C def
antithrombin III def antiphospholipid antibodies
vactor V leiden mutation
what are important components of the control mechanisms
that modulate coagulation
Antithrombin III, protein C, and protein S .
Protein S circulates in two forms:
a free form, in which
it is active as an anticoagulant; and a bound, inactive form, in which it is complexed to
C4b-binding protein of the complement system.
C4b-binding protein acts as
an acute
phase reactant. The resultant increase in inflammatory state reduces the activity of free
protein S, enhancing the likelihood of thrombosis.
in advanced HIV disease
what is the level of protein S
decreased.
is it any problem in
the measurement of the levels of protein C and protein S ( for assess for the possibility of an occult hypercoagulable state.) and why
Because protein
C and protein S are vitamin K dependent, their measurement can be problematic in
patients taking warfarin.
when is the best to measure protein C or protein S in patient who is taking the walfarin
when P. is off the warfarin for 3 to 4 weeks.
Protein C deficiency results in
a loss of ability to inactivate factor VIIa and factor Va, two
major cofactors that regulate the clotting cascade.
Warfarin lowers
protein C levels as well
as the levels of all the vitamin K-dependent clotting factors.
Because the half-lives of factor
Xa and prothrombin are longer than that of protein C, initiation of warfarin therapy
can induce
a paradoxical state of hypercoagulability.
In patients
in whom protein C deficiency is suspected,
heparin and warfarin should be initiated concomitantly.
Heparin therapy is initially started on an inpatient
basis; warfarin is indicated
for outpatient treatment. Another rare complication of warfarin therapy is skin necrosis,
which can be severe.